Table 1.
Baseline Patient Characteristics
| Characteristics | HBsAg (+), n = 12 | Isolated Anti-HBc (+), n = 46 | Anti-HBs (+), n = 35 | Overall, N = 93 |
|---|---|---|---|---|
| Age (year), mean (SD) | 55 (9) | 56 (8) | 57 (9) | 56 (8) |
| Male, n (%) | 6 (50.0) | 24 (52.2) | 16 (45.7) | 46 (49.5) |
| Prior Peg-IFN/RBV failure, n (%) | 6 (50.0) | 25 (54.3) | 17 (48.6) | 48 (51.6) |
| HCV RNA, log10 IU/mL, mean (SD) | 6.0 (2.3) | 6.4 (2.4) | 6.3 (2.5) | 6.2 (2.2) |
| HCV Genotype, n (%) | ||||
| 1a | 0 (0) | 1 (2.2) | 1 (2.9) | 2 (2.2) |
| 1b | 10 (83.3) | 38 (82.6) | 28 (80.0) | 76 (81.7) |
| 2 | 2 (16.7) | 7 (15.2) | 6 (17.1) | 15 (16.1) |
| HCV Treatment Regimen, n (%) | ||||
| LDV/SOF | 5 (50.0) | 23 (50.0) | 18 (51.4) | 46 (49.5) |
| LDV/SOF + RBV | 2 (20.0) | 9 (19.6) | 7 (20.0) | 18 (19.4) |
| SOF + RBV | 2 (16.7) | 7 (15.1) | 6 (17.1) | 15 (16.1) |
| PrOD | 2 (16.7) | 5 (10.9) | 4 (11.4) | 11 (11.8) |
| PrOD + RBV | 1 (8.3) | 2 (4.3) | 0 (0) | 3 (3.2) |
| Undetectable HBV DNA, n/n (%)a | 5 (41.7) | 0 (0) | 0 (0) | 5 (5.4) |
| METAVIR Fibrosis Stage, n (%)b | ||||
| F0/F1 | 3 (25.0) | 12 (26.1) | 9 (25.7) | 24 (25.8) |
| F2 | 3 (25.0) | 10 (21.7) | 12 (34.3) | 25 (26.9) |
| F3 | 1 (8.3) | 6 (13.0) | 3 (8.6) | 10 (10.8) |
| F4 | 4 (33.3) | 16 (34.8) | 11 (31.4) | 31 (33.3) |
| Undetermined | 1 (8.3) | 2 (4.3) | 0 (0) | 3 (3.2) |
| Hemoglobin, g/dL, mean (SD) | 14.0 (2.6) | 14.4 (2.4) | 14.2 (2.3) | 14.1 (2.9) |
| White blood cell count, 109/L, mean (SD) | 5320 (2258) | 5532 (2698) | 5038 (2379) | 5226 (2587) |
| Platelet count, 109/L, mean (SD) | 168 (54) | 162 (62) | 165 (58) | 166 (58) |
| INR, mean (SD) | 0.98 (0.08) | 1.03 (0.07) | 1.02 (0.12) | 1.01 (0.10) |
| Albumin, g/dL, mean (SD) | 4.4 (1.5) | 4.2 (1.8) | 4.4 (1.7) | 4.3 (1.7) |
| Total bilirubin, mg/dL, mean (SD) | 0.8 (0.6) | 2.2 (1.5) | 1.2 (0.7) | 2.5 (2.3) |
| Direct bilirubin, mg/dL, mean (SD) | 0.3 (0.2) | 1.2 (0.8) | 0.5 (0.3) | 1.1 (1.0) |
| ALT, U/L, mean (SD) | 92 (62) | 84 (72) | 105 (85) | 102 (78) |
Abbreviations: ALT, alanine aminotransferase; anti-HBc, hepatitis B virus core antibody; anti-HBs, hepatitis B virus surface antibody; DNA, deoxyribonucleic acid; HBsAg, hepatitis B surface agent; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; IQR, interquartile range; LDV, ledipasvir; LOD, limit of detection; Peg-IFN, peginterferon; PrOD, paritaprevir/ritonavir/ombitasvir/dasabuvir; RBV, ribavirin; RNA, ribonucleic acid; SD, standard deviation; SOF, sofosbuvir.
aDetermined by Cobas AmpliPrep/Cobas TaqMan HBV DNA test, version 2.0 with LOD of 12 IU/mL.
bDetermined by transient elastography (Fibroscan; Echosens, Paris, France) according to the cutoff values proposed by Castéra et al [14]. Two HBsAg-negative patients and 1 HBsAg-positive patient had unreliable examination with less than 10 valid measurements, a successful rate of less than 60%, and the IQR more than 30% of the median liver stiffness measurement value.